Cargando…

Stereotactic body radiotherapy (SBRT) for oligo-metastatic liver metastases from breast cancer, as an effective and safe alternative to surgery: a review

The liver is a common organ of metastases from most solid malignancies, including breast cancer, and breast cancer with liver metastases (BCLM) has a poor prognosis despite advances in systemic therapies. It has become widely recognized that local treatments for oligometastases with curative intent...

Descripción completa

Detalles Bibliográficos
Autores principales: Aoki, Shuri, Yamashita, Hideomi, Abe, Osamu, Nakagawa, Keiichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799143/
https://www.ncbi.nlm.nih.gov/pubmed/35117874
http://dx.doi.org/10.21037/tcr-20-1833
_version_ 1784641997133316096
author Aoki, Shuri
Yamashita, Hideomi
Abe, Osamu
Nakagawa, Keiichi
author_facet Aoki, Shuri
Yamashita, Hideomi
Abe, Osamu
Nakagawa, Keiichi
author_sort Aoki, Shuri
collection PubMed
description The liver is a common organ of metastases from most solid malignancies, including breast cancer, and breast cancer with liver metastases (BCLM) has a poor prognosis despite advances in systemic therapies. It has become widely recognized that local treatments for oligometastases with curative intent could improve disease control and survival outcomes under certain conditions. Regarding local therapy for BCLM, surgical resection had been the first choice though its indications were quite limited. Recently, an increasing number of prospective trials on stereotactic body radiation therapy (SBRT) for liver metastases (LMs) were published, reporting excellent tumor control with less toxicity. According to these reports, breast cancer origin is a favorable prognostic factor in SBRT for liver metastasis. Further research on patient selection and optimal dose fractionation will establish SBRT as a safe and feasible alternative treatment for resection and ablation in selected patients with BCLM. This review intends to provide evidence on the background and methods of focal radiation therapy for LMs, especially BCLM, and describes the current and future role of SBRT in the treatment of BCLM.
format Online
Article
Text
id pubmed-8799143
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-87991432022-02-02 Stereotactic body radiotherapy (SBRT) for oligo-metastatic liver metastases from breast cancer, as an effective and safe alternative to surgery: a review Aoki, Shuri Yamashita, Hideomi Abe, Osamu Nakagawa, Keiichi Transl Cancer Res Review Article on Loco-regional Therapy for Metastatic Breast Cancer The liver is a common organ of metastases from most solid malignancies, including breast cancer, and breast cancer with liver metastases (BCLM) has a poor prognosis despite advances in systemic therapies. It has become widely recognized that local treatments for oligometastases with curative intent could improve disease control and survival outcomes under certain conditions. Regarding local therapy for BCLM, surgical resection had been the first choice though its indications were quite limited. Recently, an increasing number of prospective trials on stereotactic body radiation therapy (SBRT) for liver metastases (LMs) were published, reporting excellent tumor control with less toxicity. According to these reports, breast cancer origin is a favorable prognostic factor in SBRT for liver metastasis. Further research on patient selection and optimal dose fractionation will establish SBRT as a safe and feasible alternative treatment for resection and ablation in selected patients with BCLM. This review intends to provide evidence on the background and methods of focal radiation therapy for LMs, especially BCLM, and describes the current and future role of SBRT in the treatment of BCLM. AME Publishing Company 2020-08 /pmc/articles/PMC8799143/ /pubmed/35117874 http://dx.doi.org/10.21037/tcr-20-1833 Text en 2020 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
spellingShingle Review Article on Loco-regional Therapy for Metastatic Breast Cancer
Aoki, Shuri
Yamashita, Hideomi
Abe, Osamu
Nakagawa, Keiichi
Stereotactic body radiotherapy (SBRT) for oligo-metastatic liver metastases from breast cancer, as an effective and safe alternative to surgery: a review
title Stereotactic body radiotherapy (SBRT) for oligo-metastatic liver metastases from breast cancer, as an effective and safe alternative to surgery: a review
title_full Stereotactic body radiotherapy (SBRT) for oligo-metastatic liver metastases from breast cancer, as an effective and safe alternative to surgery: a review
title_fullStr Stereotactic body radiotherapy (SBRT) for oligo-metastatic liver metastases from breast cancer, as an effective and safe alternative to surgery: a review
title_full_unstemmed Stereotactic body radiotherapy (SBRT) for oligo-metastatic liver metastases from breast cancer, as an effective and safe alternative to surgery: a review
title_short Stereotactic body radiotherapy (SBRT) for oligo-metastatic liver metastases from breast cancer, as an effective and safe alternative to surgery: a review
title_sort stereotactic body radiotherapy (sbrt) for oligo-metastatic liver metastases from breast cancer, as an effective and safe alternative to surgery: a review
topic Review Article on Loco-regional Therapy for Metastatic Breast Cancer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799143/
https://www.ncbi.nlm.nih.gov/pubmed/35117874
http://dx.doi.org/10.21037/tcr-20-1833
work_keys_str_mv AT aokishuri stereotacticbodyradiotherapysbrtforoligometastaticlivermetastasesfrombreastcancerasaneffectiveandsafealternativetosurgeryareview
AT yamashitahideomi stereotacticbodyradiotherapysbrtforoligometastaticlivermetastasesfrombreastcancerasaneffectiveandsafealternativetosurgeryareview
AT abeosamu stereotacticbodyradiotherapysbrtforoligometastaticlivermetastasesfrombreastcancerasaneffectiveandsafealternativetosurgeryareview
AT nakagawakeiichi stereotacticbodyradiotherapysbrtforoligometastaticlivermetastasesfrombreastcancerasaneffectiveandsafealternativetosurgeryareview